Avenue Therapeutics received a Nasdaq exception for continued listing on March 7, 2025, after a hearing on January 30, 2025, following a delisting notice due to insufficient stockholder equity. The company is also involved in a dispute with AnnJi Pharmaceutical over a license agreement related to its AJ201 product candidate, which AnnJi intends to terminate, claiming material breaches by Avenue.